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Abstract
Malignant tumor cells often express embryonic antigens which share the expression with embryonic stem (ES)
cells. The embryonic antigens are usually encoded by ES cell-specific genes, a number of which are associated with
tumorigenesis and/or tumor progression. We examined the expression of ES cell-specific genes in the mouse B16
melanoma cell line to identify the factors promoting tumorigenesis. We found that endogenous growth-differentia-
tion factor 3 (GDF3) expression was induced in implant B16 tumor during tumor progression in syngenic C57BL/6
mice. B16 F10, a subline with a high metastatic potential, continuously expressed GDF3 while low metastatic B16
F1 expressed comparatively decreased levels of GDF3. Overexpression of GDF3 promoted growth of implanted
melanoma B16 F1 and F10 in syngenic mice. Ectopic expression of GDF3 was accompanied by an increased level
of production of CD24/CD44. Such a profile was reported to be characteristic of melanoma stem cell-like cells.
GDF3 expression was observed in embryonal carcinomas, primary testicular germ cell tumors, seminomas and
breast carcinomas. However, the role of GDF3 in these cancers remains undetermined. Overexpression of GDF3 did
not affect the growth of mouse hepatoma high or low metastatic sublines G5 or G1, both of which do not express
GDF3. Since GDF3-driven CD24 acts as a receptor for endogenous innate immune ligands that modulate cell prolif-
eration, CD24 is an effective determinant of tumorigenesis in malignant cell transformation. Finally, our results sup-
port the view that GDF3 has the ability to induce progression of CD24-inducible melanoma in mice.
Introduction
Growth-differentiation factor 3 (GDF3) belongs to the
transforming growth factor (TGF)-b superfamily, and is
also called Vgr-2 [1,2]. Human GDF3 was first identified
during a study of cDNAs expressed in human embryonal
carcinoma cells [3]. GDF3 expression is also found in pri-
mary testicular germ cell tumors, seminomas, and breast
carcinomas. Despite its ubiquitous expression the role of
GDF3 in cancer remains undetermined [4-6]. In normal
tissues, GDF3 is expressed in embryonic stem (ES) cells
and the early embryo [7-10]. Chen et al. have demon-
strated that mice with null mutation on GDF3 exhibit
developmental abnormalities [11].
Cancers are composed of heterogeneous cell popula-
tions. The cancer stem cell (CSC) hypothesis was
advocated for acute myeloid leukemia (AML) system
[12] and recent studies have provided evidence that
solid cancers can also originated from CSCs [13]. A pre-
vious report has shown that human melanomas also
contain CSCs, and these tumor derived CSCs express
ABCB5 [14]. This investigation also reported that the
CSC population despite being very low could generate a
tumor in human melanomas [14]. A recent work has
shown that approximately 27% of human melanoma
cells could initiate a tumor [15].
Mouse melanoma B16-F10 cells also contain CSC-like
cells, which express CD133, CD44, and CD24 [16]. The
mouse melanoma CSC-like cells, when injected subcuta-
neously into syngenic mice display tumorigenic ability
[16]. Initial reports showed that the mouse CSC-like
cells are a very small population, while most cells within
the B16-F10 cell line retain the ability to induce malig-
nancy [17].
The expression of ES-specific genes is observed in sev-
eral human cancers. For example, the ES-specific gene,
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blastic leukemia [18,19]. Sall4 transgenic mice develop
AML [19], but the molecular mechanism by which this
occurs has not been shown yet. Another ES-specific gene,
Klf4, functions as either a tumor suppressor or an onco-
g e n ei nat i s s u et y p eo rc e l lc o n t e x td e p e n d e n tm a n n e r .
Klf4 expression is frequently lost in colorectal [20], gastric
[21], and bladder cancers [22]. Overexpression of Klf4 can
reduce the tumorigenicity of colonic and gastric cancer
cells in vivo [21,23]. On the other hand, high Klf4 expres-
sion levels have been detected in primary ductal carcino-
mas of the breast and oral squamous cell carcinomas
[24,25], and ectopic expression of Klf4 induced squamous
epithelial dysplasia in mice [26].
Because several ES-specific genes induce tumor pro-
gression, we tried to identify other ES-specific genes that
promote tumorigenesis. Using mouse melanoma B16-F1
and B16-F10 cell lines as a model system, we found that
GDF3 expression is different in these B16 sublines during
tumor progression. We also observed that the ectopic
expression of GDF3 promotes B16-F1 and B16-F10
tumorigensis. Interestingly, B16-F1 and B16-F10 cells
induced expression of CD133, ABCB5, CD44 and CD24,
which are expressed in mouse melanoma CSC-like cells
during tumorigenesis, and ectopic generation of GDF3
increased the CD24 expression. Since CD24 is a pattern-
recognition receptor to participate in poor prognosis in
cancer patients, we discussed the possible role of the
GDF3-CD24 pathway in tumor progression.
Results
The expression of ES cell-specific genes in mouse
melanoma B16 cells
We examined the expression of ES cell-specific genes in
mouse melanoma B16 cell lines. The mouse melanoma
B16-F10 cells were cultured in a 10-cm dish and their
total RNA was extracted. Total RNA derived from excised
C57BL/6 mouse skin was used as a control. RT-PCR ana-
lysis revealed that Sall4, Dppa5, Ecat1, and c-Myc were
expressed in B16-F10 cells in culture dish but not in
mouse skin (Figure 1A). In addition, Grb2, b-catenin, and
Stat3 were expressed more in B16-F10 than in mouse skin
(Figure 1A). Klf4 gene expression in B16-F10 cells was
almost similar to that seen in mouse skin (Figure 1A). The
expression of other genes was not detected under these
experimental conditions (Figure 1A).
Expression of ES-specific genes during tumorigenesis
Next, we examined the expression of ES-specific genes
in B16 sublines during tumorigenesis. B16-F1 or B16-
F10 cells were injected subcutaneously into C57BL/6
mice. Seven days after injection the tumor was excised
and total RNA was extracted. RT-PCR analysis revealed
that Ecat1, Dppa5, Ecat8, GDF3, Sall4, Klf4, c-Myc,
b-catenin, Stat3, and Grb2 were expressed after tumori-
genesis of B16-F1 and/or B16-F10 (Figure 1B,C).
Sall4, Grb2, b-catenin, and Stat3 are known to be
expressed in tumor cells and their roles in cancer has
been already studied [19,27,28]. Ecat1, Dppa5, and
GDF3 genes are expressed in ES cells, but their expres-
sion in tumor has not yet been reported. We initially
focused on Ecat1 and Dppa5 during tumorigenesis. To
investigate the expression kinetics we excised the B16-
F1 or B16-F10 tumor 7, 10, or 14 days after implanta-
tion, and extracted total RNA. RT-PCR analysis revealed
that Ecat1 and Dppa5 expression did not increase dur-
ing tumorigenesis in both sublines (Figure 2A and 2B).
Next, we focused on GDF3. GDF3 mRNA expression
was not detectable in B16-F1 cells cultured in dish (day
0 in Figure 2C) and only a weak expression was detected
in B16-F10 cells cultured in dish (day 0 in Figure 2D).
Interestingly, GDF3 mRNA expression increased
approximately 10-fold 7 days after s.c. inoculation in
both B16-F1 and B16-F10 cells (Figure 2C and 2D). Fol-
lowing the increase for 7 days after injection, GDF3
expression gradually decreased in B16F1 cells, but main-
tained a high level in B16-F10 cells (Figure 2E and 2F).
GDF3 promotes the tumorigenesis of B16 melanoma
GDF3 is a member of TGF-b super family which is
expressed in ES cells and in several human tumor cells.
However, the role of GDF3 during tumorigenesis remains
undetermined. To assess the functional importance of
GDF3 expression during tumorigenesis, we examined
whether the exogenous expression of GDF3 is sufficient
to promote the tumorigenesis. Murine GDF3 cDNA was
synthesized from the total RNA of B16-F1 cells and
cloned into the pEF-BOS expression vector. The trans-
fection efficiencies of this vector in B16- F1 and B16-F10
cells were ~25% with no difference between the two sub-
lines. F1 or F10 cells were transfected with empty or
GDF3-expressing vector. The following day, 1 × 10
6 of
the transfected B16-F1 or B16-F10 cells were challenged
subcutaneously into C57BL/6 mice and the tumor dia-
meters were measured. The tumor diameters of the con-
trol B16-F1 tumors were larger than the control B16-F10
tumors at days 7, 10, and 14 (Figure 3A). Interestingly,
the overexpression of GDF3 increased the tumor dia-
meters in both B16-F1 and B16-F10 cells (Figure 3A).
The promotion of tumorigenesis by GDF3 overexpres-
sion was also observed in mice injected with 1 × 10
5 of
B16-F1 or B16-F10 cells (Figure 3B).
GDF3 does not promote tumorigenesis of hepatoma G1
or G5 cells
The expression profiles of ES-specific genes from mouse
hepatoma G5 cells were different from those from B16-
F1 and B16-F10 cells (Figure 4A). We then examined
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Page 2 of 11Figure 1 Expression of ES-specific genes in mouse melanoma B16 cells. (A) Total RNA was extracted from B16-F10 cells cultured in 10-cm
dishes and RT-PCR was performed with primers listed in Table 1. Total RNA from excised C57BL/6 mice skin was used as control. B16-F10 cells
expressed mRNA of Sall4, Dppa5, Ecat1, c-Myc, Grb2, b-catenin, and Stat3, which were not expressed in control C57/BL6 skin samples. (B, C) B16-
F1 (B) or B16-F10 cells (C) were injected subcutaneously into C57BL/6 mice. Seven days after the injection, the tumor was excised. Total RNA was
extracted and RT-PCR was performed. Two additional experiments resulted in similar profiles to that shown here.
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Page 3 of 11the expression of GDF3 in mouse hepatoma G1 and G5
cell lines [29]. Unlike the mouse melanoma B16-F1 and
B16-F10 cell lines, GDF3 expression was not observed
in G1 or G5 cells in culture dish or in the cells during
tumorigenesis (Figure 4A and data not shown).
To examine whether GDF3 promotes tumorigenesis of
not only GDF3-expressing B16 melanomas but also
tumors with no expression of GDF3, we transfected the
mouse hepatoma G1 or G5 cell lines with empty or
GDF3-expressing vectors, and injected the transfected
cells into inbred BALB/c mice. Control transfected G1
or G5 cells formed tumors and the tumor size increased
for 25 days (Figure 4B). Unlike B16 melanoma cells,
forced expression of GDF3 did not result in acceleration
of tumor growth in G1 or G5 cells (Figure 4B), indicat-
ing that the ability of GDF3 to promote tumorigenesis is
specific to B16 melanoma that expresses GDF3 during
s.c. progression.
Expression of genes encoding melanoma CSCs markers
We examined the mechanism by which GDF3 acceler-
ates tumor growth. GDF3 inhibits bone morphogenetic
Figure 2 Expression kinetics of Ecat1, Dppa5, and GDF3 during tumorigenesis. B16-F1 and B16-F10 cells were injected subcutaneously into
C57BL/6 mice. Tumors were excised on the indicated day. Total RNA was extracted from the tumor and RT-PCR (A-D) or RT-qPCR (E, F) was
performed to detect Ecat1, Dppa5, and GDF3. (A, B) RT-PCR analyses revealed that mRNA of Eca1 and Dppa5 decreased during tumorigenesis. (C,
E) In B16-F1 cells, GDF3 peaked at day 7 after tumor injection and then gradually decreased. (D, F). In contrast, GDF3 expression in B16-F10 cells
increased 7 days after tumor injection and maintained a high level until 14 days after injection.
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Page 4 of 11protein (BMP) signaling. Id1 is one of the transcription
factors regulated by BMP signaling and its abnormal
expression is observed in human cancers [27,30,31].
Therefore, we examined whether the GDF3 expression
alters the Id1 expression; but no changes in Id1 expres-
sion was observed (Figure 5A).
ABCB5 is a marker of human melanoma CSCs, and
CSCs with ABCB5 have a strong ability to generate
tumors in xenotransplantation assays. Previously, Ning
Gu and his colleagues showed that CD133-, CD44-, and
CD24-positive B16-F10 cells show CSC-like feature and
have strong ability to generate tumors [16]. We examined
the expression of CD133, CD44, CD24, and ABCB5 dur-
ing tumorigenesis of B16 melanoma cells transfected
with empty or GDF3-expressing vectors. In B16-F1 cells,
expression of ABCB5, CD44, and CD24 increased during
tumorigenesis but CD133 expression was not observed at
any time points (Figure 5B). Similar to B16-F1 cells,
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Figure 3 Effect of GDF3 expression on B16 melanoma tumorigenesis.B 1 6 - F 1a n dB 1 6 - F 1 0c e l l sw e r et r a n s f e c t e dw i t he m p t yo rG D F 3 -
expressing vectors. Twenty-four hours after transfection, 1 × 10
6 (A) or 1 × 10
5 (B) cells were injected subcutaneously into C57BL/6 mice and the
tumor diameters were measured on the indicated day.
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Page 5 of 11CD24 and CD44 expression increased during B16-F10
tumorigenesis but ABCB5 expression was not observed
(Figure 5C). In contrast, CD133 expression was observed
during B16-F10 tumorigenesis (Figure 5C). Production of
GDF3 did not affect CD133, ABCB5, and CD44 expres-
sion. However, CD24 expression was higher in GDF3-
transfected B16-F1 and B16-F10 cells compared to that
of empty vector-transfected B16-F1 and B16-F10 cells
( F i g u r e5 Ba n d5 C ) .T h e s ed a t ai n d i c a t et h a tG D F 3
expression leads to increased CD24 mRNA expression or
an increase in the fraction of cells expressing CD24
mRNA.
Next, we performed FACS analysis to detect CD24-
and CD44-positive cells. B16-F10 cells transfected with
empty or GDF3-expressing vector were injected subcu-
taneously into C57BL/6 mice. Seven days after injection,
the tumor was excised, and the tumor cells were stained
with anti-CD24 and -CD44 antibodies. FACS analysis
showed that tumor cells with GDF3-expressing vector
contained more CD24 and CD44 double-positive cells
than those transfected with the empty vector (Figure 5D
and 5E). These data indicate that the expression of
GDF3 increase the number of CD24 and CD44 double-
positive cells during tumorigenesis.
Figure 4 Effect of GDF3 expression on mouse hepatoma G1 or G5 cells. (A) Total RNA was extracted from G5 cells cultured in 10-cm dishes
and BALB/c mouse liver, and RT-PCR analyses were carried out with primers listed in Table 1. (B) G1 and G5 cells were transfected with empty or
GDF3-expressing vectors. Twenty-four hours after transfection, cells were injected subcutaneously into BALB/c mice and tumor diameters were
measured on the indicated days. Two experiments with n = 4 were statistically analyzed.
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Page 6 of 11Figure 5 (A) B16-F1 cells transfected with an empty vector or a GDF3-expressing vector. Twenty-four hours after the transfection total
RNA was extracted and RT-qPCR was performed to measure the Id1 expression. “N.S.” stands for not statistically significant. (B, C) B16-F1 (B) or
B16-F10 (C) cells were transfected with empty or GDF3-expressing vectors. Twenty-four hours after transfection cells were injected
subcutaneously into C57BL/6 mice. Tumors were excised 7, 10, and 14 days after injection. Total RNA was extracted from tumors or cell from
culture (day 0) and RT-PCR was performed. (D, E) B16-F10 cells were transfected with empty (D) or GDF3-expressing vectors (E) and 24 hours
after the transfection cells were injected subcutaneously into C57BL/6 mice. The B16-F10 tumor was excised 7 days after injection. Cells were
stained with a FITC-conjugated anti-CD24 antibody and a PE-conjugated anti-CD44 antibody. Cells were analyzed by FACS. One of three similar
experiments is shown.
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Page 7 of 11Expression levels of GDF3 in implant tumor cells
We finally confirmed that GDF3-transfected F1 and F10
cells continued to express GDF3 in implant tumors. RT-
PCR analyses of excised tumors suggested that the trans-
fected F1/F10 cells expressed the mRNA of GDF3 10 days
after implantation although the levels of GDF3 mRNA
decreased after 10 days compared to day 0 (Figure 6A). A
negative control Soxl5 and a positive control b-actin were
not affected by GDF3 transfection. Protein expression of
GDF3 in F1 and F10 cells was examined by Western blot-
ting using antibody against GDF3. A representative blot-
ting profile is shown in Figure 6B. The protein as well as
mRNA amounts of GDF3 were similar in F1 and F10 cells
(Figure 6A,B). The results infer that the GDF3 message is
translated into functional protein in these tumor cells and
forced expression of GDF3 are still minimally expressed
10 days after transfection in these cells.
Discussion
We have shown that GDF3 mRNA increased during
tumorigenesis in mouse melanoma B16-F1 and B16-F10
cells. Although the genotypic and phenotypic differences
of these sublines of the same cell line origin was
described earlier [32], genes responsible for their
tumorigenic difference have not been fully elucidated.
We found that GDF3 overexpression promotes tumori-
genesis of mouse melanoma by B16-F1 and B16-F-10
cells but not hepatoma by G1 or G5 cells. Moreover,
ectopic expression of GDF3 increased CD24 expression
in both B16-F1 and B16-F10 cells. Human GDF3 is pri-
marily expressed in embryonal carcinomas, testicular
germ cell tumors, seminomas, and breast carcinomas.
H o w e v e r ,t h er o l eo fG D F 3i nt u m o r i g e n e s i sh a sn o t
been shown yet. This is the first report that establishes a
positive role of GDF3 in tumorigenesis.
Mouse melanoma CSC-like cells have a high degree of
tumorigenicity and express CD133, CD44, and CD24
[16]. The expression of these three genes increased dur-
ing B16-F10 tumorigenesis, and B16-F1 cells expressed
CD44, CD24, and ABCB5 during tumorigenesis. We
were unable to isolate the cells expressing CD44, CD24,
and CD133 (or ABCB5) from B16 tumors injected into
syngenic mice because of the low percentage of these
cells in the overall population. However, the expression
of CD24, CD44 and CD133 (or ABCB5) in melanoma
B16 cells implies that CSC-like cells emerge during
tumorigenesis. Indeed, we observed more CD24 and
CD44 double-positive cells in GDF3-expressing B16-F10
cells than in control B16-F10 cells during tumorigenesis.
But we have not yet shown the mechanism by which
Figure 6 (A) RT-PCR analysis of the GDF3 message in F1/F10 cells. F1/F10 cells were transfected with the plasmid for expression of GDF3
(upper panel). Cells just before inoculation (indicated as 0 day) and cells isolated from tumors on day 10 after inoculation (indicated as day 10)
were prepared and adjust the cell numbers. These cells were lysed and total RNA was extracted from the lysates. RT-PCR was performed to
detect GDF3 as well as Soxl5 (nagative control, center panel) and b-actin (positive control, lower panel). PCR cycles are 32 rounds, 3 times less in
those shown in Fig. 2C,D (B) Cell lysate (day 0) was subjected to SDS-PAGE (left 10% gel, right 8% gel) followed by immunoblotting. Lower
panel- Commassie brilliant blue (CBB) staining of the blot. Upper panel- blots GDF3 band visualized by treating with anti-GDF3 mAb and then
HRP-labeled 2
nd Ab. No relevant band of GDF3 was detected by CBB staining.
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Page 8 of 11GDF3 promotes turmorigenesis. The secondary effect of
GDF3 expression on other genes should not be ruled
out. One possible hypothesis is that GDF3 expression
leads to an increase of some genes in CSC-like cells and
these cells have a strong tumorigenic activity thus con-
tributing to high GDF3 tumortigenicity.
Yamanaka and his colleagues firstly showed that the
expression of four ES-specific genes, Klf4, Oct3/4, Sox2,
and c-Myc, induces pluripotent stem cell proliferation
from mouse embryonic and adult fibroblast cultures [10].
A n o t h e rr e p o r ta l s os h o w e dt h a ta n o t h e rE S - s p e c i f i c
gene Sall4 plays a positive role in the generation of pluri-
potent stem cells from blastocysts and fibroblasts [33]. In
the current CSC theory, CSCs are derived from normal
stem cells. Although several papers support this model, it
is still unknown whether all CSCs are derived from nor-
mal stem cells [13]. In general, cancer cell genome
becomes unstable because caretaker tumor suppressor
genes are mutated during carcinogenesis [34]. Genome
instability causes the expression of genes that are sup-
pressed in normal tissues. In human ES cells, GDF3 sup-
ports the maintenance of the stem cell markers, Oct4,
Nanog, and Sox2 [8,9]. Therefore, it is possible that some
fraction of cancer cells may come to express these four
genes in vivo leading to CSC formation from differen-
tiated cancer cells, and GDF3 may promote this process.
Another possibility of GDF3 role in tumorigensis is that
GDF3 modulates TGF-mediated signaling, since it
belongs to the TGF-b superfamily [8]. However, this
model cannot explain why GDF3 expression increased
only CD24 expression and not Id1 expression.
CD24 is a GPI-anchored sialoglycoprotein and is
expressed in a variety of malignant cells [35]. CD24 par-
ticipates in cell-cell contact and cell-matrix interaction
and plays a role in cell proliferation. It is currently
accepted that absence of CD24 on the tumor cell sur-
face inhibits proliferative response and induces apoptosis
in tumor cells, while up-regulation of CD24 promotes
cell proliferation to increase tumor growth and metasta-
sis [35,36]. Thus, the high CD24 level on tumor cells
may predict poor prognosis in patients with cancer. In
hepatocellular carcinoma CD24 level is actually corre-
lated with patients’ prognosis [36]. Our present finding
furthers this notion and suggests that constitutive or
forced expression of GDF3 in melanoma cells links the
high CD24 expression accelerating tumor growth. By
what mechanism TGF-b-like GDF3 induces up-regula-
tion of CD24 on tumor cells, however, remains
unknown.
In this regard, ectopic expression of GDF3 did not
promote tumorigenesis of mouse hepatoma G1 and G5
cells. The expression profiles of CD24 in B16 melanoma
sublines were parallel to those of GDF3, but hepatoma
lines G1 and G5 had impaired the ability to induce
GDF3-mediated CD24 expression. CD24 is rarely
expressed on normal cells. Only limited subsets of mye-
loid cells are CD24-positive [36]. As the signal axis of
this GDF3-derived CD24-inducing pathway is undeter-
mined, it remains unsettled as to what is the molecular
discrepancy between B16 F1/F10 melanoma cells and
G-1/G5 hepatoma cells. Furthermore, the physiological
role of the GDF3 signal and its downstream targets has
not been elucidated. Yet the GDF3-CD24 pathway fre-
quently turns positive when the cells are malignantly
transformed [37] which may support the notion that
CD24, when complexed with other molecules, alters its
function for discrimination of danger signals [37].
Although possible experiments are in progress,
another report suggests that CD24 is associated with
Siglec-10 in humans or Siglec-G in mice serve as an
innate immune receptor for endogenous self ligands
named damage associated molecular pattern (DAMP)
[38]. Accumulating evidence indicates that in tumor
progression DAMP is released from damaged tissue or
tumor cells and modulates both tumor and immune
cells. Recent report suggested that the host inflamma-
tory response to DAMP is partly controlled by a
DAMP-CD24-Siglec axis [38]. We favor the speculation
that the CD24 signals the presence of DAMP in a
tumor micro environment, thereby augmenting inflam-
matory response to facilitate pathological tumor pro-
gression in GDF3-CD24 pathway-positive B16 F1/F10
but not -negative G-1/G-5 cells. Either way, this is the
first report on the embryonic antigen GDF3 which is an
inducer of CD24 and joins tumor cell proliferation.
Further study may clarify the link between the CD24-
Siglec G pathway and innate inflammatory response
which occurs in invading tumor and facilitates to estab-
lish tumorigenesis.
Materials and methods
Cell lines and mice
B16-F1 and B16-F10 melanoma cells, G1 and G5 hepa-
toma cells were grown in RPMI1640 with 10% fetal
bovine serum. These cell lines were transfectable, and
transfection efficiencies were checked using the pEFBOS
vector for expression of GFP. The transfection efficien-
cies were ~25% in F1 and F10 cells and ~20% in G-1
and G-5 cells (data not shown). We tried to establish
stable clones constitutively expressing GDF3 in F1 and
F10 cells, but failed to establish them. C57BL/6 and
BALB/c mice (10-20 weeks of age) were purchased from
Hokudo Co. (Sapporo, Japan). All mice were maintained
under specific pathogen-free conditions in the animal
facility of the Hokkaido University Graduate School of
Medicine. Animal experiments were performed accord-
ing to the guidelines set by the animal safety center,
Japan.
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Total RNA from cells, tumors and normal tissues was
isolated using the TRIZOL reagent (Invitrogen) accord-
ing to the manufacturer’s standard instructions. Reverse
transcription was performed with random primers using
the High Capacity cDNA reverse transcription kit (ABI).
PCR was performed using primers listed in Table 1.
These primer sets are applicable to the detection of the
messages in mouse ES cells [10]. PCR cycles were
usually 35 rounds, and otherwise described. We avoided
quantitative interpretation of the results of RT-PCR ana-
lysis. The amplified DNA fragments were analyzed with
1% agarose gel and stained with etidium bromide.
Quantitative PCR
We used the following PCR primers: GDF3-F1, GDF3-
R1, b-actin-F1, and b-actin R1 for quantitative PCR.
Their sequences for GDF3 gene are listed in Table 1,
and those of b-actin are a follows: b-actin-F1: TTT
GCA GCT CCT TCG TTG C, and b-actin-R1: TCG
TCA TCC ATG GCG AAC T. Quantitative PCR was
performed by Step One real-time PCR system (ABI).
The statistical comparisons were performed using the
Student’s t test between two groups.
Tumor transplantation
B16 melanoma cells or G1, G5 hepatoma cells were cul-
tured in 10-cm dishes and harvested with 0.02% EDTA
solution. Cells were washed two times with D-PBS.
Mice were anesthetized with diethyl ether and tumor
cells were injected subcutaneously into C57BL/6 or
BALB/c mice. Tumor volumes were measured using a
caliper every 1 or 2 days. Tumor volume was calculated
using the formula: Tumor volume (cm
3)=( l o n gd i a -
meter) × (short diameter) × (short diameter) × 0.4.
Plotted data represent mean ± standard deviation (SD.).
Flow cytometry
Flow cytometry (FACS) was performed using FACS cali-
ber. Excised B16-F1 and B16-F10 tumors were treated
with collagenase D for 30 minutes and then suspended
in RPMI 1640 medium. Cells were washed two times
with FACS buffer (1 × PBS, 1% BSA, 2 mM EDTA). 1 ×
10
6 cells were suspended in 50 μl of FACS buffer. Anti
mouse CD22 and CD 44 mouse antibody (eBioscience)
were added into the cell suspension, and the cells were
incubated at 4°C for 45 minutes. After the incubation
cells were washed twice with PBS, and analyzed by
FACS caliber.
Western blot analysis
Cells were lysed in lysis buffer (20 mM Tris-HCl pH7.4,
150 mM NaCl, 1% NP-40, 10 mM EDTA, 25 mM
iodoacetamide, 2 mM PMSF, protease inhibitor mixture
(Roche)) and subjected to SDS-PAGE (8~10% gel) under
reducing conditions followed by immunoblotting with
anti-mouse GDF3 mAb or anti-b actin mAb (R&D Sys-
tems, Inc., Minneapolis, MN).
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Table 1 Primer sequences
Primer
name
Primer sequence
(F: forward)
Primer sequence
(R: reverse)
Dppa2 agaagccgtgcaaagaaaaa gttaaaatgcaacgggctgt
Fthl17 actttgggactgtgggactg ttgatagcatcctcgcactg
Sall4 gcccctcaactgtctctctg gggagctgttttctccactg
Rex1 caggttctggaagcgagttc gacaagcatgtgcttcctca
Utf1 ttacgagcaccgacactctg cgaaggaacctcgtagatgc
Tcl1 caccatgagggacaagacct cttacaccgctctgcaatca
Sox2 atgggctctgtggtcaagtc ccctcccaattcccttgtat
Dppa3 ctttgttgtcggtgctgaaa tcccgttcaaactcatttcc
Gdf3 acctttccaagatggctcct cctgaaccacagacagagca
Ecat8 tgtgtactggcaaccaaaa ctgaggtcccatcagctctc
Dnmt3l caagcctcgtgactttcctc ccatggcattgatcctctct
Eras atcctaacccccaactgtcc caagcctcgtgactttcctc
Fbxol5 ctatgattggctgcgacaga gtagtgtcgggaggcaatgt
Dppa5 cagtcgctggtgctgaaata tccatttagcccgaatcttg
Ecatl gaatgcctggaagatccaaa aaatctcagctcgcctttca
Dppa4 agggctttcccagaacaaat gcaggtatctgctcctctgg
Soxl5 cggcgtaagagcaaaaactc tgggatcactctgagggaag
Oct3/4 ccaatcagcttgggctagag ctgggaaaggtgtccctgta
Nanog cacccacccatgctagtctt accctcaaactcctggtcct
c-Myc gcccagtgaggatatcttgga atcgcagatgaagctctggt
Grb2 tcaatgggaaagatggcttc gagcatttcttctgccttgg
b-catenin gtgcaattcctgagctgaca cttaaagatggccagcaagc
Stat3 agactacaggccctcagcaa cctctgtcaggaaaggcttg
CD133 ctcatgcttgagagatcaggc cgttgaggaagatgtgcacc
CD24 actctcacttgaaattgggc gcacatgttaattactagtaaagg
CD44 gaaaggcatcttatggatgtgc ctgtagtgaaacacaacacc
ABCB5 gtggctgaagaagccttgtc tgaagccgtagccctcttta
GDF3 aaatgtttgtgttgcggtca tctggcacaggtgtcttcag
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